Aparna Renigunta
Research Subjects
Aparna Renigunta has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Ainhoa Camille Aranaga-Decori
University of the Basque Country (EHU), Leioa, Spain
2 shared publications - Alejandro García-Castaño
Biobizkaia Health Research Institute, Barakaldo, Spain
2 shared publications - Alfredo Santana
Department of Physical Education and Research Institute of Biomedical and Health Sciences (IUIBS), University of Las Palmas de Gran Canaria, Campus Universitario de Tafira s/n, 35017 Las Palmas de Gran Canaria, Spain
2 shared publications - Franziska Schilling
Marburg University, Department of Pediatric Nephrology, University Children's Hospital, Marburg, Germany
2 shared publications - Gema Ariceta
Hospital Vall d'Hebron, Barcelona, Spain
2 shared publications - Gema Fernández-Juárez
Department of Nephrology, Hospital Universitario La Paz, Madrid, Spain
2 shared publications
Latest Publications
- Open Access
- 10 August 2026
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (10) , 2249-2262
Type, Location, and Zygosity of KCNJ16 Variants May Determine the Clinical Severity of Hypokalemia Tubulopathy and Deafness
Key Points: KCNJ16 variants cause clinically heterogeneous hypokalemic tubulopathy with variable onset, severity of acidosis, and possible sensorineural deafness. Pathogenic variants affect heteromerization, membrane trafficking, and activity of the resulting channels on the basis of the type and location of the variant. Background: The pivotal role of K ir 5.1 ( KCNJ16 ) in maintaining electrolyte and acid–base homeostasis has been demonstrated in animal studies and highlighted by the identification of disease-causing variants in KCNJ16 resulting in hypokalemia tubulopathy and deafness with variable severity. Although the underlying molecular mechanisms remain elusive, the modus operandi of K ir 5.1 is deeply rooted in its heteromeric association with K ir 4.1 ( KCNJ10 ) and K ir 4.2 ( KCNJ15 ). The ubiquitous expression of KCNJ16 and heterogeneous clinical picture point toward the importance of protein–protein interactions and membrane trafficking of the heteromeric channels involving K ir 5.1. Methods: In this study, we performed whole-exome sequencing for genetic screening. Functional studies were performed in Xenopus oocytes using two electrode voltage clamp recordings. Protein–protein interactions were determined by coimmunoprecipitation. Live-cell imaging was performed using confocal microscopy to visualize the subcellular localization of the fluorescence-tagged proteins using appropriate subcellular markers. Results: Here, we report four patients from three families with salt-losing tubulopathy, hypokalemia and acidosis secondary to pathogenic biallelic variants in KCNJ16 . In addition to two previously described variants with phenotypic consistency (R137C) or phenotypic variability (I132R+R176*), we report a variant (K48*-Y57*) possibly lacking deafness, expanding the variant spectrum. Our results demonstrate that, with the exception of premature termination fragments, pathogenic K ir 5.1 variants retain interactions with K ir 4.1 and K ir 4.2 but differentially impair membrane trafficking of the heteromeric channels, offering a molecular explanation for the observed clinical heterogeneity. Conclusions: Hypokalemia tubulopathy and deafness is a clinically heterogeneous disorder where the onset, presentation, and severity may be influenced by the type and location of the KCNJ16 variants. These variant-specific effects on channel assembly, trafficking, and residual function provide a mechanistic explanation for the broad spectrum of renal and auditory phenotypes and underscore the importance of molecular characterization for accurate diagnosis and personalized therapies.
- 10 August 2026
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (10) , 2249-2262
Open AccessType, Location, and Zygosity of KCNJ16 Variants May Determine the Clinical Severity of Hypokalemia Tubulopathy and Deafness
Key Points: KCNJ16 variants cause clinically heterogeneous hypokalemic tubulopathy with variable onset, severity of acidosis, and possible sensorineural deafness. Pathogenic variants affect heteromerization, membrane trafficking, and activity of the resulting channels on the basis of the type and location of the variant. Background: The pivotal role of K ir 5.1 ( KCNJ16 ) in maintaining electrolyte and acid–base homeostasis has been demonstrated in animal studies and highlighted by the identification of disease-causing variants in KCNJ16 resulting in hypokalemia tubulopathy and deafness with variable severity. Although the underlying molecular mechanisms remain elusive, the modus operandi of K ir 5.1 is deeply rooted in its heteromeric association with K ir 4.1 ( KCNJ10 ) and K ir 4.2 ( KCNJ15 ). The ubiquitous expression of KCNJ16 and heterogeneous clinical picture point toward the importance of protein–protein interactions and membrane trafficking of the heteromeric channels involving K ir 5.1. Methods: In this study, we performed whole-exome sequencing for genetic screening. Functional studies were performed in Xenopus oocytes using two electrode voltage clamp recordings. Protein–protein interactions were determined by coimmunoprecipitation. Live-cell imaging was performed using confocal microscopy to visualize the subcellular localization of the fluorescence-tagged proteins using appropriate subcellular markers. Results: Here, we report four patients from three families with salt-losing tubulopathy, hypokalemia and acidosis secondary to pathogenic biallelic variants in KCNJ16 . In addition to two previously described variants with phenotypic consistency (R137C) or phenotypic variability (I132R+R176*), we report a variant (K48*-Y57*) possibly lacking deafness, expanding the variant spectrum. Our results demonstrate that, with the exception of premature termination fragments, pathogenic K ir 5.1 variants retain interactions with K ir 4.1 and K ir 4.2 but differentially impair membrane trafficking of the heteromeric channels, offering a molecular explanation for the observed clinical heterogeneity. Conclusions: Hypokalemia tubulopathy and deafness is a clinically heterogeneous disorder where the onset, presentation, and severity may be influenced by the type and location of the KCNJ16 variants. These variant-specific effects on channel assembly, trafficking, and residual function provide a mechanistic explanation for the broad spectrum of renal and auditory phenotypes and underscore the importance of molecular characterization for accurate diagnosis and personalized therapies.
- Open Access
Type, location and zygosity of KCNJ16 mutations may determine the clinical severity of Hypokalemic Tubulopathy and Deafness (HkTD)
The pivotal role of K ir 5.1 ( KCNJ16 ) in maintaining electrolyte and acid-base homeostasis was demonstrated by animal studies and highlighted by the identification of disease-causing mutations in KCNJ16 resulting in a complex tubulopathy with variable severity. Although the underlying molecular mechanisms remain elusive, the modus operandi of K ir 5.1 is rooted in its heteromeric association with K ir 4.1 ( KCNJ10 ) and K ir 4.2 ( KCNJ15 ). The ubiquitous expression of KCNJ16 and the heterogenous clinical picture point towards the importance of protein-protein interactions and membrane trafficking of the heteromeric channels involving K ir 5.1. Alongside a retrospective report on the R137C variant, we describe a divergent clinical phenotype in a patient compound heterozygous for I132R and R176*. Moreover, we characterize a novel variant (homozygous for K48* and Y57*) whose clinical presentation coincides with the phenotype of the Kcnj16 -/- mouse model (lack of deafness). Functional studies, buttressed by biomolecular studies (imaging and Co-IPs) in mammalian cells emphasize that the type and location of the KCNJ16 mutations may determine their interaction, membrane localization, and consequently, channel function and the resulting clinical phenotype. Our study highlights the need for molecular understanding of the KCNJ16 variants to promote correct diagnosis and personalized therapies, especially those involving channel modulators.
Open AccessType, location and zygosity of KCNJ16 mutations may determine the clinical severity of Hypokalemic Tubulopathy and Deafness (HkTD)
The pivotal role of K ir 5.1 ( KCNJ16 ) in maintaining electrolyte and acid-base homeostasis was demonstrated by animal studies and highlighted by the identification of disease-causing mutations in KCNJ16 resulting in a complex tubulopathy with variable severity. Although the underlying molecular mechanisms remain elusive, the modus operandi of K ir 5.1 is rooted in its heteromeric association with K ir 4.1 ( KCNJ10 ) and K ir 4.2 ( KCNJ15 ). The ubiquitous expression of KCNJ16 and the heterogenous clinical picture point towards the importance of protein-protein interactions and membrane trafficking of the heteromeric channels involving K ir 5.1. Alongside a retrospective report on the R137C variant, we describe a divergent clinical phenotype in a patient compound heterozygous for I132R and R176*. Moreover, we characterize a novel variant (homozygous for K48* and Y57*) whose clinical presentation coincides with the phenotype of the Kcnj16 -/- mouse model (lack of deafness). Functional studies, buttressed by biomolecular studies (imaging and Co-IPs) in mammalian cells emphasize that the type and location of the KCNJ16 mutations may determine their interaction, membrane localization, and consequently, channel function and the resulting clinical phenotype. Our study highlights the need for molecular understanding of the KCNJ16 variants to promote correct diagnosis and personalized therapies, especially those involving channel modulators.